InMed Pharmaceuticals Inc
NASDAQ:MTRI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of 
InMed Pharmaceuticals Inc (MTRI) under the Base Case is 5.53 USD per share.
Compared with the current market price of 18.6 USD, the stock appears
Overvalued by 70% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What InMed Pharmaceuticals Does
InMed Pharmaceuticals, Inc. engages in developing small molecule drug candidates targeting the CB1/CB2 receptors. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2001-06-21. The firm develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharma segment is engaged in the research and development of small molecule pharmaceuticals drug candidates.
- Headquarters
- Canada CA
- IPO date
- Jun 21, 2001
Revenue & Expenses Breakdown
InMed Pharmaceuticals Inc
Earnings Waterfall
InMed Pharmaceuticals Inc
What is the Intrinsic Value of one MTRI stock?
The intrinsic value for InMed Pharmaceuticals Inc (MTRI) under the Base Case is 5.53 USD.
Is MTRI stock undervalued or overvalued?
Compared with the current market price of 18.6 USD, the stock appears Overvalued by 70% .
